

GLAXOSMITHKLINE PLC

Form 6-K

February 12, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 12 February 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards and Shares withheld or sold to meet tax liabilities

This notification sets out the details of the vesting of awards and the sale or withholding of shares to meet tax liabilities over Ordinary Shares made in 2016 under the GlaxoSmithKline Share Value Plan (SVP), which were conditional on continued employment with the GlaxoSmithKline group. The restricted period for the 2016 SVP awards has now ended and the awards made to Persons Discharging Managerial Responsibility (PDMRs) vested on 11 February 2019.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr J Ford
  - b) Position / status SVP & General Counsel
  - c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053
  - b) Nature of the transaction The vesting and release of ADSs awarded in 2016 under the Company's 2009 Share Value Plan.
  - c) Price(s) and volume(s)
 

| Price(s) | Volume(s) |
|----------|-----------|
| n/a      | 6,320     |

 Aggregated information n/a (single transaction)
  - d) Aggregated volume  
Price
  - e) Date of the transaction 2019-02-11
  - f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr J Ford
  - b) Position / status SVP & General Counsel
  - c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|  |  |
|--|--|
|  | American Depositary Shares ('ADSs')  |
| a) Description of the financial instrument | ISIN: US37733W1053   |
| b) Nature of the transaction               | The sale of ADSs to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan. |
| c) Price(s) and volume(s)                  | Price(s)      Volume(s)<br>\$40.2654      3,113  |
| Aggregated information                     | n/a (single transaction)   |
| d) Aggregated volume                       |  |
| Price                                      |  |
| e) Date of the transaction                 | 2019-02-11   |
| f) Place of the transaction                | New York Stock Exchange (XNYS)   |

1. Details of PDMR/person closely associated with them ('PCA')

|                                     |                              |
|-------------------------------------|------------------------------|
| a) Name                             | Mr B McNamara                |
| b) Position / status                | CEO, GSK Consumer Healthcare |
| c) Initial notification / amendment | Initial notification         |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

|         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|  |  |
|--|--|
|  | American Depositary Shares ('ADSs')  |
| a) Description of the financial instrument | ISIN: US37733W1053   |
| b) Nature of the transaction               | The vesting and release of ADSs awarded in 2016 under the Company's 2009 Share Value Plan. |
| c) Price(s) and volume(s)                  | Price(s)      Volume(s)<br>n/a              11,212   |
| d) Aggregated information                  | n/a (single transaction)   |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume  
Price

e) Date of the transaction 2019-02-11

f) Place of the transaction New York Stock Exchange  
(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara

b) Position / status CEO, GSK Consumer  
Healthcare

c) Initial notification / amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

American Depositary Shares  
(‘ADSs’)

a) Description of the financial instrument  
ISIN: US37733W1053

b) Nature of the transaction  
The sale of ADSs to meet tax  
liabilities further to the  
vesting and release of the  
2016 award under the  
Company's 2009 Share Value  
Plan.

c) Price(s) and volume(s)

| Price(s)  | Volume(s) |
|---|-----------|
| \$40.2654                                       | 5,522     |
| Aggregated information n/a (single transaction) |           |

d) Aggregated volume  
Price

e) Date of the transaction 2019-02-11

f) Place of the transaction New York Stock Exchange  
(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R Simard

b) Position/status President, Pharma Supply  
Chain

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|  |   |           |
|--|---|-----------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882                            |           |
| b) Nature of the transaction               | The vesting and release of Ordinary Shares awarded in 2016 under the Company's 2009 Share Value Plan. |           |
| c) Price(s) and volume(s)                  | Price(s)  | Volume(s) |
|  | n/a   | 11,060    |
| Aggregated information                     | n/a (single transaction)  |           |
| d) Aggregated volume                       |   |           |
| e) Date of the transaction                 | 2019-02-11  |           |
| f) Place of the transaction                | London Stock Exchange (XLON)  |           |

1. Details of PDMR/person closely associated with them ('PCA')

|                                    |                                |
|------------------------------------|--------------------------------|
| a) Name                            | Mr R Simard                    |
| b) Position/status                 | President, Pharma Supply Chain |
| c) Initial notification/ amendment | Initial notification           |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

|         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|  |   |           |
|--|---|-----------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882  |           |
| b) Nature of the transaction               | The sale of Ordinary Shares to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan. |           |
| c) Price(s) and volume(s)                  | Price(s)  | Volume(s) |
|  | £15.5380  | 5,199     |
| d) Aggregated information                  | n/a (single transaction)  |           |

Aggregated volume

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Price

- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction The vesting and release of Ordinary Shares awarded in 2016 under the Company's 2009 Share Value Plan.

- c) Price(s) and volume(s)
 

|                          |           |
|--------------------------|-----------|
| Price(s)                 | Volume(s) |
| n/a                      | 11,060    |
| Aggregated information   |           |
| n/a (single transaction) |           |

- d) Aggregated volume  
Price

- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

|                              |   |           |
|------------------------------|---|-----------|
| b) Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan. |           |
| c) Price(s) and volume(s)    | Price(s)  | Volume(s) |
|                              | £15.5380  | 5,199     |
| Aggregated information       | n/a (single transaction)  |           |
| d) Aggregated volume         |   |           |
| Price                        |   |           |
| e) Date of the transaction   | 2019-02-11  |           |
| f) Place of the transaction  | London Stock Exchange (XLON)  |           |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 12, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc